Abvc Biopharma Inc (ABVC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,581 | -4,213 | -1,897 | -16,312 | -11,812 |
| Depreciation Amortization | 21 | 14 | 7 | 24 | 17 |
| Income taxes - deferred | -36 | 82 | N/A | 865 | -31 |
| Accounts receivable | 191 | 182 | 113 | -614 | -32 |
| Other Working Capital | 968 | 966 | 28 | 636 | -808 |
| Other Operating Activity | 2,680 | 572 | 252 | 8,004 | 5,728 |
| Operating Cash Flow | $-3,756 | $-2,398 | $-1,498 | $-7,398 | $-6,937 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -21 | N/A | N/A | -120 | -120 |
| Purchase Of Investment | -493 | -441 | N/A | -1,602 | -1,519 |
| Investing Cash Flow | $-514 | $-441 | $N/A | $-1,722 | $-1,638 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | -1,000 | N/A | 350 | 350 |
| Debt Issued | 1,353 | 3,175 | 3,207 | N/A | N/A |
| Common Stock Issued | 3,479 | N/A | N/A | 3,664 | 3,917 |
| Other Financing Activity | -1,000 | 0 | -1,000 | 0 | 0 |
| Financing Cash Flow | $3,832 | $2,175 | $2,207 | $4,014 | $4,267 |
| Exchange Rate Effect | 168 | 14 | -309 | -67 | -287 |
| Beginning Cash Position | 1,392 | 1,392 | 1,392 | 6,565 | 6,565 |
| End Cash Position | 1,121 | 742 | 1,792 | 1,392 | 1,970 |
| Net Cash Flow | $-271 | $-650 | $400 | $-5,174 | $-4,595 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,756 | -2,398 | -1,498 | -7,398 | -6,937 |
| Capital Expenditure | -21 | N/A | N/A | -120 | -120 |
| Free Cash Flow | -3,778 | -2,398 | -1,498 | -7,518 | -7,057 |